Ankylosing spondylitis (AS) is a common chronic rheumatic disease whose aetiology arises as a result of the contribution of environmental factors and a strong genetic component.1 One crucial point in the pathogenesis of the disease is the regulation of T cell response.2 Recently, it has been shown that the functional 1858 C/T polymorphism of PTPN22, the gene that encodes a lymphoid‐specific protein tyrosine phosphatase (LYP), is associated with several autoimmune diseases (ADs), supporting the hypothesis that common aetiopathological pathways are shared by different ADs.3 LYP has a key role as a negative regulator of T cell activation.4 It seems that the single nucleotide polymorphism (SNP) 1858 C/T disrupts the interaction between LYP and Csk, probably leading to an overactivated T cell response.5
Taking into account the functional relevance of the PTPN22 1858 C/T polymorphism, and its association with a wide range of ADs, this study aimed at investigating for the first time the possible implication of the SNP for susceptibility to AS.
A total of 197 patients with AS meeting the modified New York criteria for AS6 were recruited from Hospital Virgen de las Nieves (Granada, Spain) and Hospital Xeral‐Calde (Lugo, Spain). A total of 551 blood bank donors and bone marrow donors were included as healthy controls. All the subjects were of white Spanish origin. Samples were genotyped for PTPN22 1858C→T variants as previously described.7 Statistical analysis to compare allelic and genotypic distributions was performed by χ2 test using Statcalc program (Epi Info 2002; Centers for Disease Control and Prevention, Atlanta, GA, USA).
We found no statistically significant differences after comparing allele and genotypic frequencies of PTPN22 1858C→T between patients with AS and controls (table 1).
Table 1 Allele and genotype frequencies of the PTPN22 1858C→T polymorphism in 197 patients with AS and 551 healthy controls.
| Patients with AS | Healthy controls | p Value* | OR (95% CI) | |
|---|---|---|---|---|
| (%) | (%) | |||
| C/C | 166 (84.3) | 462 (83.8) | 0.89 | 1.03 (0.65 to 1.65) |
| C/T | 28 (14.2) | 84 (15.2) | 0.72 | 0.92 (0.56 to 1.5) |
| T/T | 3 (1.5) | 5 (0.9) | 0.47 | 1.69 (0.32 to 8.17) |
| C | 360 (91.4) | 1008 (91.5) | 0.95 | 0.99 (0.64 to 1.52) |
| T | 34 (8.6) | 94 (8.5) | 0.95 | 1.01 (0.66 to 1.55) |
*3×2 contingency table, overall p value = 0.73.
In addition, comparison of genotypes carrying the T allele (CT+TT v CC) between patients with AS and controls did not reach statistically significant skewing.
Similarly, no statistically significant differences were found when we stratified patients with AS according to HLA‐B27 status (data not shown).
The lack of association that we show here might be due to a false negative, given our underpowered sample size. Because of this, we cannot completely exclude a weak effect of this polymorphism in AS and further investigations in different populations are required.
Recent studies of the PTPN22 1858C/T polymorphism have reported a lack of association with some ADs.8 The lack of association with these ADs may indicate a common aetiological mechanism that is different from the associated ADs. It has been proposed that the susceptibility of the polymorphism may predispose individual subjects to autoimmunity by promoting the generation of autoantibodies that contribute to disease onset and progression.9 The existence of humoral abnormalities in PTPN22 knockout mice strengthens the hypothesis that autoantibody production is a prominent feature of the ADs that are associated with PTPN22.10 Based on that, the lack of autoantibody production in AS might explain the negative association between PTPN22 1858C/T polymorphism and this condition.
In conclusion, the lack of association of PTPN22 with some ADs emphasises that susceptibility factors for AD are not shared among all ADs.
Acknowledgments
This work was supported by Plan Nacional de I+D (grant SAF03‐3460) and in part by Junta de Andalucía, grupo CTS‐180. We thank Ma Paz Ruiz and Sonia Morales for excellent technical assistance.
Footnotes
Conflict of interest: None.
References
- 1.Brown M A, Crane A M, Wordsworth B P. Genetic aspects of susceptibility, severity, and clinical expression in ankylosing spondylitis. Curr Opin Rheumatol 200214354–360. [DOI] [PubMed] [Google Scholar]
- 2.Marker‐Hermann E, Schwab P. T‐cell studies in the spondyloarthropathies. Curr Rheumatol Rep 20002297–305. [DOI] [PubMed] [Google Scholar]
- 3.Siminovitch K A. PTPN22 and autoimmune disease. Nat Genet 2004361248–1249. [DOI] [PubMed] [Google Scholar]
- 4.Cloutier J F, Veillette A. Cooperative inhibition of T‐cell antigen receptor signaling by a complex between a kinase and a phosphatase. J Exp Med 1999189111–121. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M.et al A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 200436337–338. [DOI] [PubMed] [Google Scholar]
- 6.van der Linden S, Valkenburg H A, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 198427361–368. [DOI] [PubMed] [Google Scholar]
- 7.Orozco G, Sanchez E, Gonzalez‐Gay M A, Lopez‐Nevot M A, Torres B, Caliz R.et al Association of a functional single‐nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum 200552219–224. [DOI] [PubMed] [Google Scholar]
- 8.Begovich A B, Caillier S J, Alexander H C, Penko J M, Hauser S L, Barcellos L F.et al The R620W polymorphism of the protein tyrosine phosphatase PTPN22 is not associated with multiple sclerosis. Am J Hum Genet 200576184–187. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Kyogoku C, Langefeld C D, Ortmann W A, Lee A, Selby S, Carlton V E.et al Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 200475504–507. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Hasegawa K, Martin F, Huang G, Tumas D, Diehl L, Chan A C. PEST domain‐enriched tyrosine phosphatase (PEP) regulation of effector/memory T cells. Science 2004303685–689. [DOI] [PubMed] [Google Scholar]